These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21971225)

  • 1. [Treatment of multiple myeloma by immunomodulatory drugs].
    Hata H
    Rinsho Ketsueki; 2011 Oct; 52(10):1485-95. PubMed ID: 21971225
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of multiple myeloma with thalidomide and immunomodulatory drugs].
    Hattori Y
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():596-600. PubMed ID: 17476758
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
    Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
    Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
    Kourelis TV; Kumar SK; Srivastava G; Gertz MA; Lacy MQ; Buadi FK; Kyle RA; Dispenzieri A
    Leukemia; 2014 Feb; 28(2):455-7. PubMed ID: 24150218
    [No Abstract]   [Full Text] [Related]  

  • 8. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation immunomodulatory drugs in leptomeningeal myeloma.
    Bohn JP; Willenbacher W; Peschel I; Oberacher H; Steurer M
    Leuk Lymphoma; 2019 Feb; 60(2):550-552. PubMed ID: 30032690
    [No Abstract]   [Full Text] [Related]  

  • 12. Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
    Modi D; Mamdani H; Vettese T
    Am J Med Sci; 2015 Sep; 350(3):241-2. PubMed ID: 26200951
    [No Abstract]   [Full Text] [Related]  

  • 13. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
    Lacy MQ; Rajkumar SV
    Am J Hematol; 2010 Feb; 85(2):95-6. PubMed ID: 20095057
    [No Abstract]   [Full Text] [Related]  

  • 14. Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
    Vivas AC; Chimento SM; Herschthal J; Spock C; Alonso-Llamazares J
    J Am Acad Dermatol; 2013 Jun; 68(6):e179-80. PubMed ID: 23680209
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide.
    Lacy MQ; McCurdy AR
    Blood; 2013 Oct; 122(14):2305-9. PubMed ID: 23974193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomalidomide (Pomalyst) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988965
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview.
    San-Miguel JF
    Blood Rev; 2010 Nov; 24 Suppl 1():S1-3. PubMed ID: 21126631
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of immunomodulatory drugs in the treatment of solid tumors.
    Dalgleish A; Galustian C
    Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.